课题基金 / 基金详情

GI-Safer Formulation of Indomethacin for use in Preterm Neonates

GI-Safer Formulation of Indomethacin for use in Preterm Neonates
用于早产新生儿的胃肠道安全吲哚美辛制剂
批准号:
7910222
负责人:
Upendra Marathi
金额:
$15.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-05 至 2011-10-31
关键词:
AccountingAcetoneAdultAdvanced DevelopmentAffectAnimal ModelAnimal TestingAnti Inflammatory AnalgesicsAnti-Inflammatory AgentsAnti-inflammatoryApplications GrantsAspirinAttenuatedBile fluidBiological ModelsBiologyBlood CirculationBronchopulmonary DysplasiaCaliberCaringCattleCellsCessation of lifeChildhoodChronicClinicalClinical TrialsComplexComplicationComputer Systems DevelopmentCongenital Heart DefectsConsumptionDataDevelopmentDigestive System DisordersDinoprostoneDiseaseDoseDrug FormulationsEmergency SituationEnsureEpitheliumEtiologyEvaluationFamilyFrequenciesFundingGastrointestinal DiseasesGastrointestinal InjuryGastrointestinal tract structureGlucocorticoidsGoalsGrantHealth SciencesHemorrhageHospitalsIbuprofenIncidenceIndomethacinInfantInflammationInjuryIntestinal PerforationIntestinesIntravenousInvestigational New Drug ApplicationLaboratoriesLeadLecithinLegal patentLifeLow Birth Weight InfantLower Gastrointestinal TractLungManufacturer NameMethodsModelingModificationMolecularMorbidity - disease rateMucous MembraneMucous body substanceNaproxenNecrotizing EnterocolitisNeonatalNeonatal Intensive Care UnitsNon-Rodent ModelNon-Steroidal Anti-Inflammatory AgentsObstructionOperative Surgical ProceduresParticle SizePatent Ductus ArteriosusPathway interactionsPatientsPerforationPharmaceutical PreparationsPharmacologyPhasePhospholipidsPilot ProjectsPlayPre-Clinical ModelPregnancyPremature InfantPreparationPropertyRattusRegimenReplacement TherapyReportingResearch PersonnelResidual stateRiskRisk FactorsRodentRodent ModelRoleSafetySeriesSeveritiesSimulateSmall Business Innovation Research GrantSolventsSourceSterilitySurfaceTechnologyTestingTexasTissuesToxic effectToxicologyToxinTreatment EfficacyUnited States Food and Drug AdministrationUniversitiesVery Low Birth Weight InfantWeightWorkbasecommensal microbescommercializationcomparativecomparative efficacydesigneffective therapyfeedinggastrointestinalhigh riskhuman diseaseimprovedintravenous administrationintraventricular hemorrhagemedical schoolsmortalityneonatenon-drugnovelpre-clinicalprematurepreventprogramsprototypepublic health relevancepupresearch and developmentresearch studyrespiratory distress syndromescale upsoystability testingstandard of caresuccesssurfactanttrend

项目摘要

项目成果

Upendra Marathi的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请是第一阶段SBIR拨款申请。低出生体重新生儿发病和死亡的主要原因之一与下消化道损伤、炎症、穿孔和梗阻有关,可表现为相关疾病坏死性小肠结肠炎(NEC)和自发性肠穿孔(SIP)。这些消化系统疾病影响2-5%的早产儿,通常需要进行大手术,死亡率为20-50%,并已取代呼吸窘迫综合征,成为折磨这些高危新生儿患者的主要并发症。NEC和SIP的病因尚不清楚,已确定的危险因素除了体重< 1.5 kg外,还包括配方喂养和使用吲哚美辛(治疗和/或预防动脉导管未闭(PDA)发展的标准护理)。PDA是一种导致肺血管循环短路的疾病,导致氧合不足,增加脑室内出血、支气管肺发育不良和死亡的风险。在这个I期申请中,我们将进一步开发和评估一种新的吲哚美辛静脉注射,其中NSAID与磷脂酰胆碱(PC)相关,利用PLx Pharma Inc .开发的专有配方方法;该组合物将吲哚美辛与PC非共价结合,似乎可以减轻单独吲哚美辛引起的胃肠道损伤。在最初的实验中,我们将验证我们的初步观察结果,即静脉注射吲哚美辛- pc比单独使用吲哚美辛对非甾体抗炎药诱导的胃肠道出血的成年啮齿动物模型的胃肠道毒性大大降低。在这些研究之后,将对新生大鼠幼崽进行一系列试点研究,使用已建立的NEC和PDA闭合啮齿动物模型来评估我们的药物配方的GI安全性和有效性。同样在I期,我们建议优化吲哚美辛- pc的实验室配方,使其能够经过无菌过滤和包装,以确保其有足够长的保质期,以便作为“医院护理”产品供肠外使用。这些研究将在第二阶段继续和扩大,在一个更复杂的NEC仔猪模型中,它可能更接近于模拟临床情况,并与商业制造商合作进行进一步的配方开发。这些实验的结果将允许选择一个单一的,有效的铅吲哚美辛- pc配方。该赠款提案中包含的活动将显著推动Indomethacin-PC的商业化开发,并明确设计为第二阶段SBIR赠款提案的基础。如果在随后的开发工作中,吲哚美辛- pc配方被证明具有改善的胃肠道安全性,并且与吲哚美辛相比具有同等的疗效,那么它将代表着对患有潜在或确诊PDA的低出生体重新生儿治疗标准的重要改进,同时降低了发生NEC和SIP(胃肠道毁灭性疾病)的风险。
英文摘要
DESCRIPTION (provided by applicant): This application is a Phase I SBIR grant application. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, perforation and obstruction of the lower GI tract, which can be manifest in the related diseases Necrotizing Enterocolitis (NEC) and Spontaneous Intestinal Perforation (SIP). These digestive diseases, which affect 2-5% of preterm babies, frequently require major surgery and are associated with a mortality rate of 20-50%, and have replaced respiratory distress syndrome as the major complication that afflicts these high-risk neonatal patients. The etiology of both NEC and SIP have yet to be elucidated, and risk factors that have been identified, in addition to a weight of < 1.5 kg, include formula feeding and the use of indomethacin, the standard of care to treat and/or prevent the development of Patent Ductus Arteriosus (PDA). PDA is a condition which results in the circulation short circuiting the pulmonary vasculature, leading to inadequate oxygenation, increasing the risk of intraventricular hemorrhage, bronchopulmonary dysplasia, and death. In this Phase I application we will further develop and evaluate a novel indomethacin parenteral, in which the NSAID is associated with phosphatidylcholine (PC), utilizing the proprietary formulation method developed by PLx Pharma Inc; this composition non-covalently associates indomethacin with PC, which appears to reduce the GI injury caused by indomethacin alone. In the initial experiments we will validate our preliminary observations that indicate that intravenously (i.v.) administered Indomethacin-PC has a greatly reduced GI toxicity than indomethacin alone utilizing adult rodent models of NSAID-induced GI bleeding. These studies will then be followed by a series of pilot studies performed on neonatal rat pups using established rodent models of NEC and PDA closure to evaluate the GI safety and efficacy of our drug formulation. Also in Phase I, we propose to optimize the laboratory formulation of Indomethacin-PC so that it can be sterile filtered and packaged to assure a sufficiently long shelf-life for it to be used parenterally as a "hospital care" product. These studies will be continued and expanded, during Phase II in a more involved, piglet model of NEC which may more closely simulate the clinical condition, and carry out further formulation development in partnership with a commercial manufacturer. The results of these experiments will allow selection of a single, validated lead Indomethacin-PC formulation. The activities encompassed in this grant proposal will significantly advance the Indomethacin-PC development toward commercialization and are explicitly designed to serve as the basis for a Phase II SBIR grant proposal. If the Indomethacin-PC formulation is shown in subsequent development efforts to possess an improved GI safety profile, together with equivalent efficacy compared with indomethacin, it will represent an important improvement in the standard of care for the treatment of low birth weight neonates with potential or confirmed PDA, with reduced risk of developing NEC and SIP, devastating diseases of the GI tract. PUBLIC HEALTH RELEVANCE: Nearly all currently available non-steroidal anti-inflammatory drugs (NSAIDs), including indomethacin, naproxen, ibuprofen, and aspirin, cause significant GI damage. Intravenously administered indomethacin is the standard of care for the treatment of a serious cardiac defect that is common in low- and very-low birth weight infants, called patent ductus arteriosus. However, IV indomethacin frequently causes or contributes to serious GI damage that can be lethal to these infants. This grant proposal will partially fund the development of a new molecular complex of indomethacin and phosphatidylcholine, a new formulation of indomethacin that significantly reduces GI injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A small molecule integrin activator to enhance cord blood transplant
  • 批准号:
    9139272
  • 项目类别:
  • 资助金额:
    $29.59万
  • 财政年份:
    2016
  • 负责人:
    Upendra Marathi
  • 依托单位:
A small molecule integrin activator to enhance cord blood transplant
  • 批准号:
    9907800
  • 项目类别:
  • 资助金额:
    $93.6万
  • 财政年份:
    2016
  • 负责人:
    Upendra Marathi
  • 依托单位:
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
  • 批准号:
    9138564
  • 项目类别:
  • 资助金额:
    $31.37万
  • 财政年份:
    2016
  • 负责人:
    Upendra Marathi
  • 依托单位:
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
  • 批准号:
    8313502
  • 项目类别:
  • 资助金额:
    $56.54万
  • 财政年份:
    2010
  • 负责人:
    Upendra Marathi
  • 依托单位:
海外基金